- Frailty assessment
- Support for older patients with cancer
- Management of polypharmacy
- Examples of good practice
It is aimed at professions from all backgrounds with an interest in improving outcomes for older people with cancer.
Servier was founded in 1954 in France and in 1963 Servier UK was the first subsidiary to open. Servier has a unique cultural heritage as an independent pharmaceutical group. It is present in 149 countries, with more than 22,000 employees including close to 3,000 in research and development.
Servier invests only in therapeutic areas where there is a real unmet medical need and develop truly innovative drugs to improve the quality of people’s lives. As a private research foundation, Servier has no shareholders and the freedom to prioritise research over profits. Revenue generated by its medicines is used to fund ongoing research.
Rosemont's mission is to improve the health, quality of life and wellbeing of vulnerable patients through the development, manufacture and supply of high-quality prescription oral liquid medicines. Its ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them.
Rosemont has a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including 70 licensed products. Its UK range also includes 9 products licensed for use with PEG/NG tubes. It is seeking to expand its range of medicines and convert its ‘specials’ to licensed products wherever possible.
In addition to its extensive range of liquid medicines, Rosemont also provides a wide variety of resources designed to support healthcare professionals deliver the best possible care for their patients. Resources include further information on swallowing difficulties and product education.
With a portfolio spanning from prescription drugs and consumer healthcare products to dermo-cosmetics, Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. Its portfolio includes several global brands and franchises, such as Pierre Fabre Dermatologie and Pierre Fabre Oncologie. Pierre Fabre is committed to delivering treatment options to patients with cancer and has been working with oncologists for 30 years to make a difference in their clinical practice.
Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation. Pierre Fabre Limited is the UK subsidiary of Pierre Fabre.
Pierre Fabre has funded the educational/scientific content of this meeting only. It has not been involved with or influenced the content, agenda or speaker selection.
Click here to be kept up to date with this and future events https://www.surveymonkey.co.uk/r/mailinglistsignup